Kymera Therapeutics Presents Preclinical Data for Anti-Inflammatory Drug KT-474
02:41 PM EDT, 05/10/2021 (MT Newswires) -- Kymera Therapeutics (KYMR) said it has presented positive preclinical data for its anti-inflammatory drug candidate KT-474 at the annual meeting of the American Association of Immunologists.
The product is currently in Phase I clinical testing for immune-inflammatory diseases such as atopic dermatitis and rheumatoid arthritis.
Data shows KT-474's efficacy and superiority to IRAK4 small molecule inhibitors across multiple mechanistic and disease models of inflammation, the company said.
Data will continue to be presented through May 15.
Price: 43.60, Change: -0.45, Percent Change: -1.02